Machine-written from the fields above · claude-haiku-4-5-20251001
The Food and Drug Administration classified cardiovascular machine learning-based notification software as class II medical devices, effective September 11, 2026.
The Food and Drug Administration classified cardiovascular machine learning-based notification software as class II medical devices, effective September 11, 2026. — via Downstream, https://downstream.sh/daily/agency/health-and-human-services-department/#s-2026-09-11
Post on X
Post on LinkedIn
Permalink
NoticeHealth and Human Services DepartmentNational Institutes of Health
91 FR 57900FR Doc. 2026-18615official PDF↗federalregister.gov↗
RuleHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA) is classifying the cardiovascular machine learning-based notification software into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the cardiovascular machine learning- based notification software. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
- ○Takes effect today
91 FR 57785FR Doc. 2026-18612official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentCenters for Medicare & Medicaid Services
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, and to allow a second opportunity for public comment on the notice. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
- ○Comments close in 32 days
91 FR 57892FR Doc. 2026-18611official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentHealth Resources and Services Administration
HRSA is providing additional funding under the Appalachian Region Healthcare Support Program to one award recipient in fiscal year (FY) 2026. This supplemental funding will support additional technical assistance (TA) to help rural healthcare organizations located in the rural counties served by the Appalachian Regional Commission to strengthen healthcare delivery in the region.
91 FR 57897FR Doc. 2026-18570official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentHealth Resources and Services Administration
HRSA is providing additional award funds to 11 current ITCP-- State Award recipients previously funded under HRSA-22-73 to support the continuation and expansion of existing activities to build state and local capacity and implement the infant-toddler court approach in federal fiscal year (FY) 2026.
91 FR 57898FR Doc. 2026-18568official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentHealth Resources and Services Administration
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
- ○Comments close in 60 days
91 FR 57897FR Doc. 2026-18553official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA or Agency) is announcing the availability on its website of the final administrative order (final order) (OTC000008-1) titled "Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate." This final order amends "Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use" (Over- the-Counter (OTC) Monograph M020) to remove PABA and trolamine salicylate as sunscreen active ingredients. A sunscreen drug product containing PABA or trolamine salicylate is not generally recognized as safe and effective (GRASE).
91 FR 57892FR Doc. 2026-18551official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection requirements for the tracking of medical devices.
- ○Comments close in 60 days
91 FR 57893FR Doc. 2026-18529official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA or the Agency) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
- ○Comments close in 32 days
91 FR 57895FR Doc. 2026-18528official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentHealth Resources and Services Administration
HRSA is awarding supplemental funding under the Rural Hospital Stabilization Pilot Program to two award recipients in fiscal year (FY) 2026 to provide in-depth technical assistance (TA) to rural hospitals to enhance and/or expand service lines to meet local needs and keep health care services available locally.
91 FR 57899FR Doc. 2026-18518official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentNational Institutes of Health
91 FR 57901FR Doc. 2026-18514official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentNational Institutes of Health
91 FR 57900FR Doc. 2026-18513official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentNational Institutes of Health
91 FR 57900FR Doc. 2026-18512official PDF↗federalregister.gov↗
Machine-written from the fields above · claude-haiku-4-5-20251001
The Food and Drug Administration published eight medical device classifications, one food additive petition withdrawal, one priority review voucher fee notice, and three funding or programmatic notices.
The Food and Drug Administration published eight medical device classifications, one food additive petition withdrawal, one priority review voucher fee notice, and three funding or programmatic notices. — via Downstream, https://downstream.sh/daily/agency/health-and-human-services-department/#s-2026-09-10
Post on X
Post on LinkedIn
Permalink
Proposed RuleHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA or we) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 2323) proposing that the food additive regulations be amended to provide for the safe use of hydrolyzed lignin as a source of neutral detergent soluble fiber in food for broiler chickens, laying hens, turkeys, growing swine, sows, lactating dairy cows, beef cattle, sheep, goats, salmonids, and adult dogs at no more than 1% of the food on a weight basis or 10 kilograms per metric ton of food.
91 FR 57531FR Doc. 2026-18469official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA or the Agency) is announcing the fee rate for using a priority review voucher for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended, authorizes FDA to determine and collect priority review user fees for certain applications for review of human drug or biological products when those applications use a tropical disease, rare pediatric disease, or material threat medical countermeasure (MCM) priority review voucher. These vouchers are awarded to the sponsors of tropical disease, rare pediatric disease, or material threat MCM product applications, respectively, that meet the requirements of the FD&C Act, upon FDA approval of such applications. The amount of the fee for using a priority review voucher is determined each fiscal year, based on the difference between the average cost incurred by FDA to review a human drug application designated as priority review in the previous fiscal year, and the average cost incurred in the review of an application that is not subject to priority review in the previous fiscal year. This notice establishes the FY 2027 priority review fee rate applicable to submission of eligible applications for review of human drug or biological products using a tropical disease, rare pediatric disease, or material threat MCM priority review voucher and outlines the payment procedures for such fees.
- ○Takes effect in 20 days
91 FR 57617FR Doc. 2026-18464official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentNational Institutes of Health
91 FR 57620FR Doc. 2026-18441official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentNational Institutes of Health
The National Center for Advancing Translational Sciences (NCATS) will host a public online roundtable to share the latest updates on how NCATS is advancing translational science research and provide an opportunity for an interactive discussion with NCATS director Dr. Joni Rutter.
91 FR 57621FR Doc. 2026-18440official PDF↗federalregister.gov↗
RuleHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA) is classifying the mechanical deviation device for esophageal protection during cardiac ablation procedures into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the mechanical deviation device for esophageal protection during cardiac ablation procedures. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
- ○Takes effect 1 days ago
91 FR 57495FR Doc. 2026-18433official PDF↗federalregister.gov↗
RuleHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA) is classifying the temperature regulation device for esophageal protection during cardiac ablation procedures into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the temperature regulation device for esophageal protection during cardiac ablation procedures. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
- ○Takes effect 1 days ago
91 FR 57500FR Doc. 2026-18432official PDF↗federalregister.gov↗
RuleHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA) is classifying the extravascular support for an arteriovenous fistula for vascular access into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the extravascular support for an arteriovenous fistula for vascular access. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
- ○Takes effect 1 days ago
91 FR 57498FR Doc. 2026-18431official PDF↗federalregister.gov↗
RuleHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA) is classifying the anti-tumor necrosis factor alpha monoclonal antibody test system for inflammatory bowel disease into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the anti-tumor necrosis factor alpha monoclonal antibody test system for inflammatory bowel disease. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
- ○Takes effect 1 days ago
91 FR 57493FR Doc. 2026-18430official PDF↗federalregister.gov↗
RuleHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA) is classifying the cooperative powered surgical assist device for ear, nose, and throat (ENT) surgery into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the cooperative powered surgical assist device for ENT surgery. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
- ○Takes effect 1 days ago
91 FR 57502FR Doc. 2026-18429official PDF↗federalregister.gov↗
RuleHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA) is classifying the implanted tibial electrical urinary continence device into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the implanted tibial electrical urinary continence device. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
- ○Takes effect 1 days ago
91 FR 57504FR Doc. 2026-18428official PDF↗federalregister.gov↗
RuleHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA) is classifying the vaginal hydrogel packing system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the vaginal hydrogel packing system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
- ○Takes effect 1 days ago
91 FR 57509FR Doc. 2026-18427official PDF↗federalregister.gov↗
RuleHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA) is classifying the whole room microbial reduction device into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the whole room microbial reduction device. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
- ○Takes effect 1 days ago
91 FR 57507FR Doc. 2026-18426official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentHealth Resources and Services Administration
HRSA is providing additional fiscal year 2026 funding under the Medicare Rural Hospital Flexibility (Flex) Program using the program's established funding methodology, including a baseline increase for all recipients and an additional adjustment for states with newly designated Critical Access Hospitals (CAHs). This funding will support state efforts to strengthen CAHs, improve quality and performance, and sustain access to essential rural health care services.
91 FR 57619FR Doc. 2026-18425official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentCommunity Living Administration
The Administration for Community Living (ACL) announces the intent to award a single-source supplement to the current cooperative agreement held by the Northeast Iowa Area Agency on Aging (NEI3A) for the SMP Resource Center. The administrative supplement for FY 2026 will be in the amount of $226,000, bringing the total award for FY 2026 to $1,226,000. The supplement will allow the grantee to expand activities that began in FY 2025, which includes testing new communications strategies, expanding the functionality of their SMP smart phone app, exploring partnerships with technology companies, and other activities all aimed at expanding the reach of SMP messaging.
91 FR 57616FR Doc. 2026-18415official PDF↗federalregister.gov↗
Machine-written from the fields above · claude-haiku-4-5-20251001
The Food and Drug Administration published guidance on temporary policies for compounding starter parenteral nutrition drug products for neonates.
The Food and Drug Administration published guidance on temporary policies for compounding starter parenteral nutrition drug products for neonates. — via Downstream, https://downstream.sh/daily/agency/health-and-human-services-department/#s-2026-09-09
Post on X
Post on LinkedIn
Permalink
NoticeHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a guidance for industry titled "Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates." This guidance describes the FDA's regulatory and enforcement priorities regarding the compounding of certain starter parenteral nutrition drug products for neonates by outsourcing facilities and by State-licensed pharmacies and Federal facilities that are not registered with FDA as outsourcing facilities. This guidance is being published for immediate implementation due to the expected market exit of the predominant source of certain starter parenteral nutrition drug products for neonates in the United States.
91 FR 57358FR Doc. 2026-18368official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
91 FR 57359FR Doc. 2026-18349official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection associated with statutory and regulatory requirements that govern certain human cells, tissues, and cellular and tissue-based products (HCT/Ps).
- ○Comments close in 59 days
91 FR 57347FR Doc. 2026-18333official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentCenters for Medicare & Medicaid Services
In accordance with the Privacy Act of 1974, as amended, the Department of Health and Human Services (HHS) is modifying an existing system of records maintained by the Centers for Medicare & Medicaid Services (CMS), titled "Hospice Item Set (HIS) System," System No. 09-70-0548. The amended System of Records Notice (SORN) reflects changes to now include real time data collection at the time of patient assessments to improve the understanding of patient care needs and care coordination. CMS is also changing the name of the system of records to "Hospice Outcomes and Patient Evaluation (HOPE)" and making other modifications which are explained in the Supplementary Information section. The HOPE system collects standardized hospice patient data to measure and improve care quality, support regulatory and reporting requirements, and enable research and policy functions.
- ○Takes effect in 28 days
91 FR 57344FR Doc. 2026-18316official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ANDEMBRY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.
- ○Comments close in 178 days
91 FR 57356FR Doc. 2026-18300official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on a proposed study entitled "Pregnancy Exposure Registry Enrollment Project: A Survey of Health Care Providers to Advance Pregnancy Safety Data Collection and Improve Health Communications."
- ○Comments close in 59 days
91 FR 57352FR Doc. 2026-18299official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ANZUPGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
- ○Comments close in 178 days
91 FR 57355FR Doc. 2026-18298official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ANKTIVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.
- ○Comments close in 178 days
91 FR 57350FR Doc. 2026-18297official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentHealth Resources and Services Administration
HRSA is publishing this notice of petitions received under the National Vaccine Injury Compensation Program (the Program), as required by the Public Health Service (PHS) Act, as amended. While the Secretary of HHS is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.
91 FR 57361FR Doc. 2026-18283official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentCenters for Disease Control and Prevention
CDC has modified its structure. This notice announces the reorganization of the National Center for Immunization and Respiratory Diseases (NCIRD). NCIRD has consolidated offices, retitled divisions and branches, and modified mission and function statements.
- ○Takes effect 7 days ago
91 FR 57343FR Doc. 2026-18263official PDF↗federalregister.gov↗
Machine-written from the fields above · claude-haiku-4-5-20251001
The Department of Health and Human Services published six notices on September 8, 2026, including information collection requests and a Medicare town hall meeting announcement.
The Department of Health and Human Services published six notices on September 8, 2026, including information collection requests and a Medicare town hall meeting announcement. — via Downstream, https://downstream.sh/daily/agency/health-and-human-services-department/#s-2026-09-08
Post on X
Post on LinkedIn
Permalink
NoticeHealth and Human Services DepartmentHealth Resources and Services Administration
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
- ○Comments close in 59 days
91 FR 57155FR Doc. 2026-18235official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentCenters for Medicare & Medicaid Services
This notice announces a town hall meeting in accordance with section 1886(d)(5)(K)(viii)(III) of the Social Security Act (the Act) to discuss fiscal year (FY) 2028 applications for add-on payments for new medical services and technologies under the hospital inpatient prospective payment system (IPPS). Interested parties are invited to this virtual meeting to present their comments, recommendations, and data regarding whether the FY 2028 applications for new technology add- on payments meet the substantial clinical improvement criterion.
91 FR 57153FR Doc. 2026-18226official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentCenters for Disease Control and Prevention
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Possession, Use, and Transfer of Select Agents and Toxins (42 CFR 73). This data collection allows CDC and APHIS have to collect information on the possession, use, and transfer of select agents and toxins.
- ○Comments close in 59 days
91 FR 57150FR Doc. 2026-18217official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentNational Institutes of Health
91 FR 57159FR Doc. 2026-18215official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentNational Institutes of Health
91 FR 57156FR Doc. 2026-18193official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentNational Institutes of Health
In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.
- ○Takes effect in 27 days
91 FR 57157FR Doc. 2026-18191official PDF↗federalregister.gov↗
No sentence for this date — either it has not been generated yet, or it was withheld by the fidelity gate.
Proposed RuleHealth and Human Services DepartmentChildren and Families Administration
The Department of Health and Human Services, Administration for Children and Families proposes to remove the Care and Treatment of Mentally Ill Nationals of the United States, Returned from Foreign Countries regulations to streamline regulations and to renumber it under a different Part.
- ○Comments close in 24 days
91 FR 56826FR Doc. 2026-18167official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentFood and Drug Administration
The Food and Drug Administration (FDA or Agency) is opening a public docket to solicit comments on FDA's efforts to advance development of botanical drug products (BDPs). FDA is publishing this request for information to better understand stakeholders' perspectives on the state of BDP development in the United States, challenges encountered, and potential solutions to gathering the information required by the Federal Food, Drug, and Cosmetic Act (FD&C Act).
- ○Comments close in 53 days
91 FR 56887FR Doc. 2026-18133official PDF↗federalregister.gov↗
NoticeHealth and Human Services Department
The Department of Health and Human Services (HHS) is publishing the names of the Performance Review Board Members (PRB) who are reviewing performance of Senior Executive Service members, Title 42 executives, Senior Level, and Scientific Professional employees for Fiscal Year 2026.
91 FR 56890FR Doc. 2026-18120official PDF↗federalregister.gov↗
NoticeHealth and Human Services DepartmentHealth Resources and Services Administration
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.
- ○Comments close in 24 days
91 FR 56889FR Doc. 2026-18115official PDF↗federalregister.gov↗